Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home/Insights/Future directions in endocrinology, diabetes and metabolism

Future directions in endocrinology, diabetes and metabolism

Prevention and disease modification rather than glucose control, and a reckoning with who can afford any of it.

Endocrinology, diabetes and metabolism

Disease modification and prevention

In type 1 diabetes, the direction is from treating established disease toward delaying or preventing onset in identified at-risk individuals, which requires population screening for islet autoantibodies and an infrastructure to monitor those identified.

In type 2 diabetes, remission through weight reduction — surgical, dietary or pharmacological — has shifted the framing from lifelong progressive disease to a potentially reversible one, with durability the open question.

Beta-cell replacement

Stem cell-derived islet replacement is the long-standing goal, with immune protection — avoiding lifelong immunosuppression — the principal obstacle. It should be read as advancing but not established.

Precision

Type 2 diabetes is heterogeneous, and sub-classification by phenotype or genotype aims at matching treatment to subtype. Monogenic diabetes is the proof that classification changes treatment; whether the same holds across common type 2 subtypes is unresolved.

The hard constraint

The most effective recent therapies are expensive, and diabetes prevalence is rising fastest in low- and middle-income settings. Insulin access remains a problem a century after its discovery.

The gap between what is possible and what is delivered is now the dominant issue in this field, and it is a health-systems question rather than a pharmacological one.

Methodological direction

Longer follow-up for durability. Hard outcomes rather than HbA1c. Trials conducted in the populations where burden is greatest rather than only where trial infrastructure exists — a generalisability problem that currently limits what the evidence can support.

In short

What to take from this.

  • Remission durability is unresolved — do not present it as established.
  • Beta-cell replacement is advancing, not established.
  • Trial populations do not match where disease burden is greatest.

Sources

  • Established literature on type 1 diabetes prevention and screening
  • Type 2 diabetes remission evidence
  • Global access literature on insulin and diabetes care

This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.